Who is eligible for clinical trial NCT07662135?

Participants must meet the protocol's inclusion criteria for Type 2 Diabetes Mellitus. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07662135 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-03

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (NCT07662135)

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (8 items).

Location: Research Site — Peoria, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening
On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)
HbA1c value:
On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol/mol)
SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol/mol)
Impaired renal function
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
Severe congestive heart failure (New York Heart Association IV)
History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (185 Sites)

Showing the first 25 of 185 sites.

Research Site — Peoria, Arizona
Research Site — Surprise, Arizona
Research Site — Concord, California
Research Site — Sacramento, California
Research Site — Victorville, California
Research Site — Fleming Island, Florida
Research Site — Lauderdale Lakes, Florida
Research Site — Leesburg, Florida
Research Site — Miami Lakes, Florida
Research Site — Ocoee, Florida
Research Site — Orlando, Florida
Research Site — Chicago, Illinois
Research Site — Braintree, Massachusetts
Research Site — New Bedford, Massachusetts
Research Site — Worcester, Massachusetts
Research Site — Saint Joseph, Michigan
Research Site — Saint Paul, Minnesota
Research Site — Kansas City, Missouri
Research Site — Omaha, Nebraska
Research Site — Las Vegas, Nevada
Research Site — Albuquerque, New Mexico
Research Site — The Bronx, New York
Research Site — Kinston, North Carolina
Research Site — Raleigh, North Carolina
Research Site — Winston-Salem, North Carolina

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Type 2 Diabetes Mellitus

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study — Aurora, Colorado
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes — Tucson, Arizona
Preventing Type 2 Diabetes in Black Emergent Adult — Chapel Hill, North Carolina
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System — Los Angeles, California
A Study of Glycemic Control in Left Ventricular Assist — Rochester, Minnesota
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus — Mesa, Arizona

Explore by condition: All Type 2 Diabetes Mellitus clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗